Spanish DNActive raises €370k to assess disease risk in patients and provide personalised treatments

DNactive

Could we avoid most diseases if we just knew more about our DNA? Granada-based DNActive is trying to do exactly that, with a mission to improve the quality of life of patients through innovative treatments based on their DNA.

The startup, which develops genetic tests and creates customised products based on them, has just raised a financing round of €370k on the investment platform SociosInversores.com.

Founded in 2016, DNActive is able to determine a person’s predisposition to major diseases and pathologies such as diabetes, osteoporosis, and celiac disease through a personalised genetic tests. The startup can determine an individual’s risk, and use that as a basis to provide personalised guidelines such as disease prevention plans, diets, exercises, or supplements, to prevent the disease from appearing or mitigate its symptoms. It works with clinics and laboratories, pharmacies, and directly with patients through its website.

DNActive aspires to position itself as a strategic player in genetics and medtech sector. With the funding, it will expand the number of services in different health verticals and the number of possible personalised products for the prevention and treatment of pathologies. DNActive has so far showed impressive growth in Spain, with turnover increasing by a factor of four in 2018 over 2017, and plans to expand internationally.

MIGHT BE INTERESTING FOR YOU:

LEAVE A REPLY

Please enter your comment!
Please enter your name here